Background--Left ventricular dysfunction and heart failure are strongly associated in humans with increased circulating levels of proinflammatory cytokines, T cells, and soluble intercellular cell adhesion molecule 1 (ICAM1). In mice, infiltration of T cells into the left ventricle contributes to pathological cardiac remodeling, but the mechanisms regulating their recruitment to the heart are unclear. We hypothesized that ICAM1 regulates cardiac inflammation and pathological cardiac remodeling by mediating left ventricular T-cell recruitment and thus contributing to cardiac dysfunction and heart failure.
T he complex syndrome of heart failure (HF) is a leading cause of morbidity and mortality worldwide.
1 Systemic serum markers of inflammation including the proinflammatory cytokines interleukin (IL) 1b and IL-6 as well as tumor necrosis factor a and soluble intercellular cell adhesion molecule 1 (ICAM1) 2 correlate with cardiac dysfunction and HF. [3] [4] [5] [6] Nevertheless, clinical trials using tumor necrosis factor a inhibitors failed to improve HF outcomes, 7, 8 emphasizing the need to better understand the mechanisms by which systemic inflammation influences the pathogenesis of HF. We and others showed high levels of circulating T cells in humans with HF, further supporting a role for systemic T-cell-mediated inflammation in HF. [9] [10] [11] Moreover, we recently demonstrated that T cells play a critical role in the pathogenesis of pressure overload-induced HF. Specifically, T cells were found to infiltrate the left ventricle (LV) of humans and mice with nonischemic HF, and the absence of T cells resulted in preserved cardiac systolic and diastolic function in a mouse model of pressure overload-induced HF. T-cell recruitment to the LV was found to be essential to the pathogenesis of HF 9 ; however, the mechanisms by which T cells are recruited to the LV in nonischemic HF remain poorly understood. ICAM1, an immunoglobulin-like adhesion molecule that mediates leukocyte arrest and transendothelial migration from the blood stream to the site of inflamma-tion, 12, 13 is highly expressed in human intramyocardial vascular endothelium during myocardial infarction. 14 Similarly, in experimental models of HF induced by suprarenal abdominal aortic constriction, ICAM1 expression is upregulated in the heart within the first week. 15 We recently demonstrated increased ICAM1 expression in the vascular endothelium in mice after pressure overload-induced HF in association with LV systolic dysfunction and LV T-cell infiltration. 9 Consequently, we hypothesized that ICAM1 mediates T-cell infiltration in the LV in response to pressure overload and contributes to cardiac remodeling and dysfunction during HF progression.
In the present study, we determined the dynamics of intramyocardial ICAM1 induction in mice subjected to pressure overload induced by transverse aortic constriction (TAC) and examined the pressure overload response of mice with genetic deletion of ICAM1. We showed, for the first time, that ICAM1-deficient (ICAM1 À/À ) mice are protected from maladaptive cardiac remodeling and HF through mechanisms that include decreased cardiac fibrosis and CD3 + T-cell and Ly6C high monocyte-mediated cardiac inflammation. We have also identified a mechanism by which ICAM1 is upregulated in the LV that is independent of endothelial cell-specific mineralocorticoid receptor (EC-MR) signaling because mice deficient in EC-MR (EC-MR À/À ) have increased LV endothelial ICAM1 expression and similar numbers of LV-infiltrated T cells compared with EC-MR +/+ mice.
Methods Mice
Mice were bred and maintained under pathogen-free conditions and treated in accordance with the guidelines of the National Institutes of Health for the care and use of laboratory animals. All protocols were approved by the Tufts Medical Center institutional animal care and use committee. Thirty male C57BL/6 wild-type (WT) mice, 31 male ICAM1
À/À mice 16 (provided by Dan Bullard, University of Alabama, Birmingham), and 11 EC-MR knockout EC-MR À/À and EC-MR +/+ male littermates 17 were euthanized at age 10 to 14 weeks for tissue collection. The overall number of mice corresponding to each experiment is indicated in the related figure legend.
Mouse Model of TAC
Pressure overload was induced by constricting the transverse aorta of male mice aged 8 to 10 weeks, as described previously, to induce HF. 18, 19 Sham-operated mice underwent the same procedure but without constriction (4-8 per group unless otherwise indicated). At 48 hours and at 2 and 4 weeks after TAC, mice were euthanized and tissue was harvested for further analysis, as described. 9 Quantitative Polymerase Chain Reaction of LV Samples
Total RNA was extracted from mouse heart LV tissues directly using Trizol (Invitrogen). RNA was then reverse-transcribed to cDNA following Applied Biosystems' protocol using MuLV reverse transcriptase and amplified by real-time polymerase chain reaction (PCR) with SYBR green PCR mix (Applied Biosystems). Samples were quantified in triplicate using 40 cycles performed at 94°C for 30 seconds, 60°C for 45 seconds, and 72°C for 45 seconds using an ABI Prism 7900 Sequence Detection System (Applied Biosystems). The following primer sequences were used: Icam1, forward 
Immunohistochemistry and Histological Analysis
Heart samples were excised, and the LV was separated from the right ventricle. Sections of the LV were immediately embedded in OCT or fixed in 10% formalin, embedded in paraffin, and cut into 5-lm LV sections. Hematoxylin and eosin or picrosirius red staining was performed, as described previously. 20, 21 Serial OCT frozen cryostat sections were stained with anti-mouse CD54 (YN1/1.7.4), anti-mouse CD31 (MEC13.3), or anti-mouse CD4 (GK1.5) purchased from BioLegend.
Quantitative Flow Cytometry
Flow cytometry was performed to analyze the immune profile present in response to TAC. The data were acquired on a FACSCanto analyzer (Becton Dickinson) and analyzed using FlowJo software. LV digested with collagenase type II (0.895 mg/mL) and protease XIV (0.5 mg/mL) and lymphoid organs were harvested from sham-operated and TAC mice and stained with the following monoclonal antibodies: FITC-conjugated anti-CD4 (GK1.5), APC-Cy7-conjugated anti-CD4 (GK1.5), FITC-conjugated anti-CD3e (145-2C11), PE-conjugated anti-CD45.2 (104), APC-Cy7-conjugated anti-Ly-6C (HK1.4), PerCP-conjugated anti-CD11b (M1/70), APC-Cy7-conjugated anti-CD44 (IM7), and PE-conjugated anti-CD62L (MEL-14). All antibodies were purchased from BioLegend. Cells were surface stained by incubation with the relevant antibodies diluted in PBS plus 2% FBS for 20 minutes at room temperature, followed by 2 washes with PBS plus 2% FBS.
Adult Mouse Cardiac Myocyte Isolation
Cardiac myocytes were isolated from WT and ICAM1
À/À hearts 4 weeks after TAC, as described previously. 22 
Cardiac Fibroblast Isolation and Differentiation to Myofibroblast
Perfused hearts from male WT and ICAM1 À/À mice aged 8 to 10 weeks were digested with Liberase DL (Roche) for 25 minutes at 37°C. The resulting cell suspension was cultured in fibroblast growth media on 1% gelatin-coated plates. Purified cardiac fibroblast in passages 2 to 3 were treated with transforming growth factor b (100 ng/mL for 16 hours) to induce fibroblast transition to myofibroblasts, which was determined by measuring mRNA levels of a-smooth muscle actin.
LV In Vivo Hemodynamic Studies
In vivo LV function was assessed by pressure-volume analysis in mice anesthetized with 2.5% isofluorane. A 1.4F pressurevolume catheter (SPR-839; Millar Instruments) was advanced through the carotid artery and across the aortic valve into the LV. The absolute volume was calibrated, and pressure-volume data were assessed at steady state and during preload reduction. Hemodynamics were recorded and analyzed with IOX version 1.8.11 software (EMKA Instruments).
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In Vivo Transthoracic Echocardiography M mode and 2-dimensional images were obtained from the short-axis view, as described previously. 
Statistical Analysis
Data are expressed as the meanAESEM. Statistical analyses were performed with the unpaired Student t test or nonparametric Mann-Whitney test, as indicated, using GraphPad Prism software (GraphPad Software). When the unpaired t test was used, the outcome was confirmed to be normally distributed. When the nonparametric Mann-Whitney test was used, each condition's median and interquartile range was reported in the figure legend corresponding to each data set. Differences were considered statistically significant at P<0.05.
Results

Upregulation of ICAM1 in the LV in Response to TAC
To investigate the kinetics of endothelial cell activation during the progression of HF, we determined the expression of ICAM1 in the LV of WT mice at 48 hours and at 2 and 4 weeks after inducing LV pressure overload by TAC. We observed significant upregulation of ICAM1 mRNA in the LV of TAC mice compared with sham-operated mice as early as 48 hours after TAC, which progressively increased by 2 and 4 weeks after TAC ( Figure 1A ). Endothelial ICAM1 protein expression followed kinetics similar to the LV mRNA, remaining significantly upregulated during the period of progressive systolic dysfunction and T-cell infiltration, as shown previously. 9 Platelet/endothelial cell adhesion molecule 1 was used to stain the intramyocardial endothelial vessels in parallel with ICAM1 in the same sections and was, as expected, constitutively expressed and not induced in response to TAC ( Figure 1B ). Taken together, our data demonstrate that endothelial ICAM1 is upregulated during the course of TAC as HF progresses, raising the question of whether ICAM1 mediates T-cell infiltration of the LV later on as HF progresses and contributes to local cardiac inflammation and systolic dysfunction in response to LV pressure overload.
ICAM1 Is Required for Leukocyte Infiltration Into the LV in Response to TAC
Given the well-known role of ICAM1 as an endothelial cell adhesion molecule mediating leukocyte recruitment into tissues, the observed upregulation of ICAM1 in the intramyocardial vessels in response to TAC, and the recent findings that T cells infiltrate the LV and contribute to the pathogenesis of HF in response to TAC, 9,24 we evaluated whether ICAM1 was required for T-cell infiltration of the pressureoverloaded LV using WT and ICAM1 À/À mice. In contrast to WT mice, in which CD45.2 + leukocytes infiltrated the LV in response to TAC, pressure overload did not induce a significant increase in LV leukocyte infiltration in ICAM1 to TAC, and given the role of T cells in cardiac fibrosis in this model, 9 we hypothesized that ICAM1 À/À mice would not develop cardiac fibrosis in response to TAC. TAC induced an expected increase in both LV interstitial ( Figure 5A ) and perivascular ( Figure 5B ) fibrosis in WT mice. In contrast, LV fibrosis was completely absent in ICAM1 À/À mice in response to TAC ( Figure 5A and 5B). Markers of fibrosis such as transforming growth factor b, collagen type I, and a-smooth muscle actin were also elevated in WT mice in response to TAC but not in ICAM1 À/À mice ( Figure 6A through 6C Table) . These studies demonstrated that ICAM1 contributes to cardiac dysfunction in response to pressure overload induced by TAC.
ICAM1 Upregulation in the Pressure-Overloaded LV is Independent of EC-MR Signaling and Associated With Early Upregulation of Cardiac IL1b and IL-6
We explored potential mechanisms that may be driving the increase in ICAM1 expression in cardiac endothelial cells in response to pressure overload. Mineralocorticoid receptor signaling is known to be activated in HF, and prior studies demonstrate that EC-MR activation upregulates the expression of ICAM1 in vitro in human coronary endothelial cells 27 and in the heart in vivo in response to constriction of the ascending aorta. 28 Based on these data, we hypothesized that EC-MR signaling drives LV endothelial ICAM1 upregulation in response to TAC. To test this hypothesis, we subjected EC- Representative pictures are shown (magnification 920). Scale bar=50 lm. Statistical analysis used the unpaired t test. C through E, Quantitative reverse transcription polymerase chain reaction of the hypertrophy markers (C) BNP and (D) ANP and the (E) ratio of eling progressed ( Figure 8D) . Altogether, our studies demonstrated that EC-MR does not play a role in endothelial LV ICAM1 upregulation and suggested a mechanism by which IL-1b and IL-6 produced by resident LV cells as early as 48 hours after TAC induce endothelial ICAM1, which drives LV leukocyte infiltration, further cardiac inflammation, and adverse cardiac remodeling in an EC-MR-independent manner.
Discussion
This study demonstrates that ICAM1 functions as a critical regulator of pathological cardiac remodeling in pressure overload-induced HF by mediating the recruitment of proinflammatory leukocytes in the LV, leading to cardiac inflammation, cardiac fibrosis, and cardiac dysfunction. We report for the first time that ICAM1 À/À mice are protected from cardiac inflammation and fibrosis and do not develop HF in the setting of LV pressure overload. We provide a mechanism by which T cells and proinflammatory monocytes are recruited to the LV via intramyocardial endothelial ICAM1, which is upregulated independent of EC-MR signaling. Our data suggest that ICAM1 upregulation in the heart may be temporally related to pressure overload induction of cardiac IL-1b and IL-6, known activators of ICAM1 expression. Our findings also suggest that ICAM1 expression in antigenpresenting cells is not necessary for T-cell activation in the heart-draining lymph nodes at the onset of HF induced by LV pressure overload. Our data support a model in which LV pressure overload initially results in cardiac cytokine release that induces endothelial ICAM1 expression, in turn promoting later leukocyte recruitment to the LV in the onset of HF. Once infiltrated, LV leukocytes further release cytokines and promote cardiac inflammation, cardiac fibrosis, and cardiac dysfunction resulting in HF. In the absence of ICAM1, leukocyte recruitment, cardiac inflammation, and fibrosis are significantly reduced and result in improved cardiac function. Our data positions ICAM1 as a central player in pressure overload-induced HF. Multiple studies over the years have identified ICAM1 as a critical regulator of leukocyte arrest and transendothelial migration to allow leukocyte tissue infiltration in cardiovascular disease. 12, 30, 31 In the human heart, endothelial ICAM1 is upregulated after myocardial infarction, correlating with high infiltration of inflammatory leukocytes. 14 We and others have shown that endothelial ICAM1 is upregulated at the onset of pressure overload induced by either TAC or suprarenal abdominal aortic constriction in rodents, concomitantly with cardiac inflammation and T-cell infiltration of the LV. 9, 15, 32 These data led us to hypothesize that ICAM1 mediates T-cell recruitment to the LV during pathological cardiac remodeling in HF. Our data confirm that expression of endothelial ICAM1 at 2 and 4 weeks after TAC correlates with T-cell infiltration of the LV and with a highly proinflammatory cytokine environment that can result in intramyocardial endothelial cell activation. Moreover, we demonstrated LV endothelial ICAM1 as early as 48 hours after TAC, preceding LV leukocyte infiltration. 9 Our studies using ICAM1 À/À mice and quantitative flow cytometry demonstrate for the first time that Ly-6C high monocytes, known to play a role in cardiac remodeling after myocardial infarction, 33, 34 are also recruited to the LV together with T cells in response to TAC at 4 weeks. Our results are in line with a recent report that suggests Ly6C high monocytes play a role in maladaptive cardiac remodeling at 3 weeks after TAC, whereas Ly6C low monocytes participate in early adaptive cardiac remodeling to TAC. 35 We also demonstrated that this process is ICAM1 dependent, positioning ICAM1 as a major contributor to cardiac inflammation, which likely contributes to the pathogenesis of HF in this model of pressure overload-induced HF. Although ICAM1 was originally cloned from endothelial cells, it is now known to be expressed on essentially all leukocyte subsets in addition to vascular endothelial cells. 36 These leukocytes include several antigen-presenting cells in which ICAM1 functions as an accessory molecule in the immune synapse in response to some specific antigens. 36 Consequently, ICAM1 expressed in nonendothelial cells also likely contributes to the phenotype of the ICAM1 À/À mice.
Nevertheless, our findings suggest that ICAM1 expressed by antigen-presenting cells does not play a role in T-cell activation in response to TAC because T cells were activated similarly in the heart-draining lymph nodes of WT and ICAM1 À/À mice in response to TAC. Although the antigens activating the T-cell immune response in TAC remain unknown, 9,24 we interpret our findings as suggesting that the antigens involved in this response do not require ICAM1 in the immune synapse for optimal presentation to achieve T-cell activation. In addition, the similar frequencies of activated T cells and blood-circulating CD4 + T cells in sham-operated WT and ICAM1 À/À mice are in line with the initial description of ICAM1 À/À mice, indicating no differences in circulating T cells compared with WT mice. 16 Moreover, the frequency of circulating T cells was also similar between WT and ICAM1 À/À mice in response to TAC, suggesting that the reduced LV T-cell infiltration observed in ICAM1 À/À mice is not due to a defect in T-cell activation promoted by antigenpresenting cell-expressed ICAM1 but rather to a defect in LV T-cell infiltration mediated by endothelial ICAM1.
We interpret our findings indicating that ICAM1 À/À mice develop LV hypertrophy but not fibrosis and systolic and diastolic dysfunction as supporting the intriguing possibility that ICAM1 normally promotes a pathological hypertrophic program, whereas deletion of ICAM1 is sufficient to retain a compensatory hypertrophy phenotype during pressure overload. The lack of transition to the fetal or pathological gene expression pattern, including atrial and brain natriuretic peptides and myosin heavy chain b observed in ICAM1 ; however, we also demonstrated that pharmacological depletion of T cells did not prevent cardiac hypertrophy in response to TAC, despite preventing cardiac dysfunction, 9 similar to our results in ICAM1 À/À mice and to a previous report that neutralized ICAM1 pharmacologically in rats during pressure overload. 15 We speculate that in pharmacologically T-cell-depleted mice, in ICAM1 À/À mice, and in ICAM1-inhibited rats, the remaining T cells that infiltrate the LV can still contribute to hypertrophy by secreting prohypertrophic mediators such as angiotensin II. 39 Interestingly, in all of these settings in mice, we observed blunted LV fibrosis in response to TAC. Our in vitro data demonstrated that ICAM1 expressed in monocytes and fibroblasts is not required for their transition to profibrotic macrophages or myofibroblasts in vitro. These data suggest that the lack of fibrosis in ICAM1 À/À mice in vivo is related to a lack of endothelial ICAM1 that prevents T-cell infiltration, which is necessary for fibrosis. We cannot rule out a role for nonendothelial ICAM1 in vivo, and this possibility will require further investigation in tissue-specific ICAM1-deficient mice. Alternatively, soluble ICAM1 resulting from matrix metalloprotease and elastase cleavage of membrane-bound ICAM1 36 could also contribute to cardiac inflammation by acting on b2-integrins in infiltrated leukocytes and inducing their proinflammatory activation, as described in a model of lung injury. 40 Soluble ICAM1 has also been shown to engage unknown receptors in the central nervous system and to trigger Src activation, 41 and Src, p38 MAPK, and ERK1/2 are involved in cardiac hypertrophy and fibrosis. Elucidation of the mechanisms that drive the upregulation of endothelial ICAM1 represent an important avenue in understanding of the contribution of ICAM1 and proinflammatory leukocyte recruitment to cardiac dysfunction and failure. The mineralocorticoid receptor is activated by the hormone aldosterone, which is elevated in serum in humans with HF and in animal models of HF induced by aortic constriction. [48] [49] [50] Aldosterone induces ICAM1 expression in human coronary artery endothelial cells in vitro through its actions via mineralocorticoid receptor signaling. 27 Our results demonstrating that ICAM1, IL-1b, and IL-6 levels in the LV and LV T-cell infiltration are similarly induced in EC-MR À/À and EC-MR +/+ mice in response to TAC suggest that ICAM1 is upregulated independently of EC-MR signaling. Consequently, our data suggest that ICAM1 may instead be upregulated in response to the cytokines IL-1b and IL-6, which have been shown previously to be expressed by cardiac-resident cells under stress 51, 52 and are known to mediate endothelial cell activation. 29 Moreover, our results suggest that the beneficial effect of aldosterone antagonists in HF patients may occur independently of EC-MRs that involve ICAM1-mediated LV leukocyte infiltration and may be due to mineralocorticoid receptor inhibition in other cells including macrophages and cardiomyocytes, as demonstrated previously in mouse models of hypertension-mediated cardiomyophathy using tissuespecific deletion of mineralocorticoid receptor. 53, 54 Collectively, our findings demonstrate for the first time that ICAM1 is necessary for pressure overload-induced cardiac inflammation, fibrosis, and resulting cardiac dysfunction and HF. Our data provide an ICAM1-dependent mechanism through which effector T cells are recruited into the LV in response to pressure overload, perhaps due to cardiac expression of cytokines that activate endothelial ICAM1 expression. Future studies using tissue-specific ICAM1-deficient mice will explore whether ICAM1 expressed in other cell compartments in the heart in addition to the endothelium may contribute to maladaptive cardiac remodeling in HF. Our data provide a mechanism through which effector T cells are recruited into the LV in response to pressure overload. This understanding supports the potential to target ICAM1-mediated T-cell recruitment into the LV to improve the function of the failing heart. Paruchuri, from Tufts Medical Center (TMC), for their support in cardiac myocyte isolation from adult mice and experimental advice, respectively. Nathan Li from the Histology core at Tufts University, and the members of the Molecular Cardiology Research Institute (TMC), Boston, MA, for helpful suggestions and discussions of this article.
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